Bulletin
Investor Alert

Market Pulse Archives

May 27, 2021, 5:59 a.m. EDT

Sanofi and GlaxoSmithKline begin Phase 3 study of COVID-19 vaccine candidate

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Sanofi ADR (SNY)
  • X
    GlaxoSmithKline PLC ADR (GSK)
  • X
    GlaxoSmithKline PLC (GSK)

or Cancel Already have a watchlist? Log In

By Barbara Kollmeyer

French pharmaceutical group Sanofi /zigman2/quotes/201967021/composite SNY -1.63% [s:fr: san] and U.K. drug company GlaxoSmithKline /zigman2/quotes/209463850/composite GSK +0.49% /zigman2/quotes/200381158/delayed UK:GSK +0.65% said they have begun global Phase 3 efficacy studies of their jointly produced COVID-19 candidate. The randomized, double-blind placebo controlled study will involve more than 35,000 volunteers aged 18 and older from the U.S., Africa, Asia and Latin America. In a two-stage approach, the study will first look at how effective the vaccine is against the original D.614 (Wuhan) virus, and then see how it works against the B.1.351 South African variant. The Phase 3 design also allows for evaluation of the vaccine against a variety of those circulating variants. Pending a positive outcome of the trials and regulatory reviews, the vaccine could be authorized in the final quarter of this year, while manufacturing will start in the coming weeks to ensure rapid access to the vaccine that happen, the companies said in a statement.

/zigman2/quotes/201967021/composite
US : U.S.: Nasdaq
$ 51.24
-0.85 -1.63%
Volume: 1.56M
Jan. 21, 2022 4:00p
P/E Ratio
18.66
Dividend Yield
2.67%
Market Cap
$129.54 billion
Rev. per Employee
$434,064
loading...
/zigman2/quotes/209463850/composite
US : U.S.: NYSE
$ 45.10
+0.22 +0.49%
Volume: 5.47M
Jan. 21, 2022 4:00p
P/E Ratio
19.20
Dividend Yield
4.43%
Market Cap
$111.81 billion
Rev. per Employee
$484,678
loading...
/zigman2/quotes/200381158/delayed
UK : U.K.: London
1,647.20 p
+10.60 +0.65%
Volume: 8.03M
Jan. 21, 2022 4:35p
P/E Ratio
19.29
Dividend Yield
4.86%
Market Cap
£82.49 billion
Rev. per Employee
£354,283
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.